{
    "clinical_study": {
        "@rank": "21646", 
        "arm_group": [
            {
                "arm_group_label": "Placebo (Multiple dose part)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablet"
            }, 
            {
                "arm_group_label": "Dose 2, EM, single dose", 
                "arm_group_type": "Experimental", 
                "description": "Extensive Metaboliser (EM), single dose part, medium dose"
            }, 
            {
                "arm_group_label": "Dose 3, EM, single dose", 
                "arm_group_type": "Experimental", 
                "description": "Extensive Metaboliser (EM), single dose part, high dose"
            }, 
            {
                "arm_group_label": "Dose 3, PM, single dose", 
                "arm_group_type": "Experimental", 
                "description": "Poor Metaboliser (PM), single dose part, high dose"
            }, 
            {
                "arm_group_label": "Dose 3, PM, multiple dose", 
                "arm_group_type": "Experimental", 
                "description": "Poor Metaboliser (PM), multiple dose part, high dose"
            }, 
            {
                "arm_group_label": "Placebo (Single dose part)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablet"
            }, 
            {
                "arm_group_label": "Dose 1, EM, single dose", 
                "arm_group_type": "Experimental", 
                "description": "Extensive Metaboliser (EM), single dose part, low dose"
            }
        ], 
        "brief_summary": {
            "textblock": "Safety, tolerability and pharmacokinetics of  single and multiple oral doses of BI 409306\n      tablets in healthy Chinese and Japanese male volunteers of a known genotype as specified in\n      the study protocol."
        }, 
        "brief_title": "Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy male Chinese and Japanese volunteers\n\n          2. Age between 20 and 45 years\n\n          3. BMI between 18.5 and 25 kg/m2 (Body Mass Index)\n\n          4. Known genotype as specified in the study protocol\n\n          5. Subjects must be able to understand and comply with study requirements\n\n        Exclusion criteria:\n\n        1. Any deviation from healthy condition"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841112", 
            "org_study_id": "1289.4"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose 1, EM, single dose", 
                "description": "tablet", 
                "intervention_name": "BI 409306", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 3, EM, single dose", 
                "description": "tablet", 
                "intervention_name": "BI 409306", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 3, PM, single dose", 
                "description": "tablet", 
                "intervention_name": "BI 409306", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 3, PM, multiple dose", 
                "description": "tablet", 
                "intervention_name": "BI 409306", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (Multiple dose part)", 
                "description": "placebo tablet", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (Single dose part)", 
                "description": "placebo tablet", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 2, EM, single dose", 
                "description": "tablet", 
                "intervention_name": "BI 409306", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "July 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "1289.4.8201 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "7", 
        "official_title": "Safety, Tolerability and Pharmacokinetics of Single Oral Doses of BI 409306 (Tablet) in Healthy Chinese and Japanese Male Volunteers and Multiple Oral Doses of BI 409306 (Tablet) in Healthy Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety (MFDS)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The number (%) of subjects with drug related Adverse Events", 
            "safety_issue": "No", 
            "time_frame": "up to 13 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841112"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 13 days"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 13 days"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma from time 0 to time of last quantifiable data point )", 
                "safety_issue": "No", 
                "time_frame": "up to 13 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}